netFormulary The Pennine Acute Hospitals NHS
NHS Trust Formulary  
 Search
 Recent Updates - Updated items

All Formulary Amendments

  Records 1 to 11 of 11


Details
LDL Link Added : NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion : https://www.nice.org.uk/guidance/ta305
08/02/2018 14:56:38
(SBoulger )
LDL Link Added : NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion : https://www.nice.org.uk/guidance/ta409
08/02/2018 14:55:58
(SBoulger )
LDL Link Added : NICE TA346: Aflibercept for treating diabetic macular oedema : https://www.nice.org.uk/guidance/ta346
08/02/2018 14:54:15
(SBoulger )
LDL Link Added : NICE TA486: Aflibercept for treating choroidal neovascularisation : https://www.nice.org.uk/guidance/ta486
08/02/2018 14:53:23
(SBoulger )
LDL Link Added : GMMMG: Macular Drugs Pathway : http://gmmmg.nhs.uk/docs/guidance/GMMMG-Macular-Drugs-Pathways-v-1-2-FINAL.pdf
08/02/2018 14:52:24
(SBoulger )
UPD Aflibercept (Eylea) Restriction
08/02/2018 14:49:56
(SBoulger )
UPD Aflibercept (Eylea) First choice alongside Lucentis
08/02/2018 14:43:11
(SBoulger )
UPD Aflibercept (Eylea) red
01/09/2015 14:04:30
(ec01ph )
UPD Aflibercept (Eylea) Clinically approved for neovascular (wet) age-related macular degeneration (AMD) as per NICE TA294 Not currently approved for Central Vein Occlusion
07/01/2015 15:55:56
(ec01ph )
UPD Aflibercept (Eylea) Clinically approved for neovascular (wet) age-related macular degeneration (AMD)by Surgical D&T on 26/11/14
07/01/2015 15:53:50
(ec01ph )
UPD Aflibercept (Eylea) formulary
07/01/2015 15:51:32
(ec01ph )

 

 

netFormulary